691905-10-9

Upstream product

• 123843-65-2 2,6-difluoro-4-methoxybenzoic acid 
• 140-88-5 ethyl acrylate 
• 256417-10-4 2,6-difluoro-4-methoxybenzaldehyde 
• 858114-78-0 ethyl (2E)-3-(2,6-difluoro-4-methoxyphenyl)acrylate 

Downstream Products

• 691905-11-0 ethyl 3-(2,6-difluoro-4-hydroxyphenyl)-propanoate 
• 691902-74-6 3-{4-[(2',6'-dimethylbiphenyl-3-yl)methoxy]-2,6-difluorophenyl}propanoic acid 
• 691902-73-5 ethyl 3-(2,6-difluoro-4-((2',6'-dimethylbiphenyl-3-yl)methoxy)phenyl)propanoate 

Relevant academic research and scientific papers

Design, synthesis, and biological activity of potent and orally available g protein-coupled receptor 40 agonists

G protein-coupled receptor 40 (GPR40) is being recently considered to be a new potential drug target for the treatment of type 2 diabetes because of its role in the enhancement of free fatty acid-regulated glucose-stimulated insulin secretion in pancreatic β-cells. We initially identified benzyloxyphenylpropanoic acid (1b) (EC50 = 510 nM), which was designed based on the structure of free fatty acids, as a promising lead compound with GPR40 agonist activity. Chemical modification of compound 1b led to the discovery of 3-{4-[(2′,6′-dimethylbiphenyl-3-yl)methoxy]-2- fluorophenyl}propanoic acid (4p) as a potent GPR40 agonist (EC50 = 5.7 nM). Compound 4p exhibited acceptable pharmacokinetic profiles and significant glucose-lowering effects during an oral glucose tolerance test in diabetic rats. Moreover, no hypoglycemic event was observed even after administration of a high dose of compound 4p to normal fasted rats. These pharmacological results suggest that GPR40 agonists might be novel glucose-dependent insulin secretagogues with little or no risk of hypoglycemia.

Rh(I)-catalyzed decarboxylative transformations of arenecarboxylic acids: Ligand- and reagent-controlled selectivity toward hydrodecarboxylation or heck-mizoroki products

(Chemical Equetion Presentation) A Rh(I)-based catalyst system has been developed to promote three types of decarboxylative transformations of arenecarboxylic acids: (1) hydrodecarboxylation, (2) Heck-Mizoroki olefination, and (3) conjugate addition. Scopes of reactions (1) and (2) were studied, and the ligand and reagent dependence of selectivity was explored.

PHENYLPROPANOIC ACID DERIVATIVES

The present invention provides a novel compound having a GPR40 receptor function modulating action, which is useful as an insulin secretagogue, a drug for the prophylaxis or treatment of diabetes and the like. A compound represented by the formula (I) wherein each symbol is as defined in the specification, a salt thereof and a prodrug thereof have unexpectedly superior GPR40 receptor agonist activity and also show superior properties as a pharmaceutical product, such as stability and the like. Thus, they can be safe and useful drugs for the prophylaxis or treatment of GPR40 receptor related conditions or diseases in mammals.

ALKOXYPHENYLPROPANOIC ACID DERIVATIVES

The present invention aims at provision of a novel compound having a GPR40 receptor function modulating action, which is useful as an insulin secretagogue, an agent for the prophylaxis or treatment of diabetes and the like. The compound represented by the formula: wherein each symbol is as defined in the description, a salt thereof, and a prodrug thereof of the present invention unexpectedly have a superior GPR40 receptor agonistic activity and superior properties as pharmaceutical products such as stability and the like, and can be safe and useful pharmaceutical agents as agents for the prophylaxis or treatment of GPR40 receptor-related pathology or diseases in mammals.

RECEPTOR FUNCTION CONTROLLING AGENT

The GPR40 receptor function regulator of the present invention, which comprises a compound having an aromatic ring and a group capable of releasing cation is useful as an insulin secretagogue or an agent for the prophylaxis or treatment of diabetes and the like.